Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
New Gold Opportunities in the Cariboo Region (CSE:GCC) (OTC:GCCFF) (click to learn more) Why Herbal Dispatch (CSE:HERB) Is Getting Attention (click to learn more) Atlas Salt Expands MOU with Sandvik Mining Supporting Great Atlantic Salt Project (click to learn more) Digital Health Meets AI -CSE: ALEN.U (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

OPKO Health Inc OPK

Healthcare Diagnostics & Research
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, immunology, and infectious diseases; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly admi...


NDAQ:OPK - Post by User

OPKO Health Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(59)
•••
  • NibinatorX
Post by Nibinatoron Mar 31, 2024 9:05pm
122 Views
Post# 35962051

BUY BUY BUY BUY BUY

BUY BUY BUY BUY BUYI starting the day with this ... high hopes sings frankie boy
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities